Development stages
Full pipeline overview
All programmes are investigational. Not approved for any indication.
| Programme | Discovery | Preclinical | IND / CE-enabling | Clinical / Launch |
|---|---|---|---|---|
| PLA-REGEN Regenerative | ||||
| PLA-CHEMO-1 Oncology | ||||
| PLA-ONCO-1 Oncology | ||||
| PLA-ONCO-2 Oncology |
Programme detail
Programme by programme
PLA-REGEN
Regenerative- Indication
- Regenerative medicine (aesthetic, orthopaedics, ophthalmology, wound care)
- Payload
- RNA-enriched platelet preparation (enhanced PRP / hPL kit)
- Regulatory route
- Under definition (EU)
- Notes
- Regulatory classification under definition with the competent authorities. Not yet CE-marked. Lead indication: aesthetic (cash-pay).
Stage progression
PLA-CHEMO-1
Oncology- Indication
- Solid tumours (lead: pancreatic cancer)
- Payload
- Gemcitabine
- Regulatory route
- ATMP / Hospital Exemption (EU) · IND / 505(b)(2) (US)
- Notes
- Entering preclinical. 505(b)(2) regulatory optionality (US).
Stage progression
PLA-ONCO-1
Oncology- Indication
- Pancreatic ductal adenocarcinoma (PDAC)
- Payload
- siRNA vs KRAS G12D
- Regulatory route
- ATMP / Hospital Exemption (EU) · IND (US)
- Notes
- Entering preclinical. First-in-class genetic payload via PTT.
Stage progression
PLA-ONCO-2
Oncology- Indication
- Solid tumours (to be determined)
- Payload
- Genetic payload (TBD)
- Regulatory route
- TBD
- Notes
- Discovery-stage programme. Payload and indication under evaluation.
Stage progression
Regulatory & forward-looking statement notice
All Plasfer programmes are investigational and have not been approved by any regulatory authority. PLA-REGEN's regulatory classification is being defined with the competent authorities and it is not yet CE-marked. PLA-CHEMO-1 and PLA-ONCO-1 are in preclinical development; no IND or CTA has been filed. Programme timelines and regulatory routes are subject to change. No claims of safety or efficacy are made. This content may contain forward-looking statements; actual results may differ materially.
Interested in co-developing a PTT programme?
We are open to scientific collaboration, licensing discussions, and co-development agreements for payload classes and indications outside Plasfer's current portfolio.